Search Results - "Gore, M E"

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities by Sinha, R., Edmonds, K., Newton-Bishop, J.A., Gore, M.E., Larkin, J., Fearfield, L.

“…Summary Until recently, no effective treatment was available for patients with metastatic malignant melanoma, and median overall survival was little more than…”
Get full text

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma by Motzer, R J, Escudier, B, Bukowski, R, Rini, B I, Hutson, T E, Barrios, C H, Lin, X, Fly, K, Matczak, E, Gore, M E

“…Background: Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (⩾30 months) were investigated in sunitinib-treated…”
Get full text

A study of the decision outcomes and financial costs of multidisciplinary team meetings (MDMs) in oncology by De Ieso, P B, Coward, J I, Letsa, I, Schick, U, Nandhabalan, M, Frentzas, S, Gore, M E

“…Background: The benefits of multidisciplinary working in oncology are now accepted as the norm and widely accepted as being pivotal to the delivery of optimal…”
Get full text

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer by Glasspool, R M, Brown, R, Gore, M E, Rustin, G J S, McNeish, I A, Wilson, R H, Pledge, S, Paul, J, Mackean, M, Hall, G D, Gabra, H, Halford, S E R, Walker, J, Appleton, K, Ullah, R, Kaye, S

“…Background: Our previous laboratory and clinical data suggested that one mechanism underlying the development of platinum resistance in ovarian cancer is the…”
Get full text

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies by Gore, M E, Larkin, J M G

“…Optimum efficacy is the primary goal for any cancer therapy, and entails controlling tumour growth and prolonging survival as far as possible. The prognosis…”
Get full text

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma by Hutson, T E, Bukowski, R M, Rini, B I, Gore, M E, Larkin, J M, Figlin, R A, Barrios, C H, Escudier, B, Lin, X, Fly, K, Martell, B, Matczak, E, Motzer, R J

“…Background: We retrospectively analyzed sunitinib outcome as a function of age in metastatic renal cell carcinoma (mRCC) patients. Methods: Data were pooled…”
Get full text

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma by O'Day, S, Pavlick, A, Loquai, C, Lawson, D, Gutzmer, R, Richards, J, Schadendorf, D, Thompson, J A, Gonzalez, R, Trefzer, U, Mohr, P, Ottensmeier, C, Chao, D, Zhong, B, de Boer, C J, Uhlar, C, Marshall, D, Gore, M E, Lang, Z, Hait, W, Ho, P

“…Background: α v integrins are involved in angiogenesis and melanoma tumourigenesis. Intetumumab (CNTO 95) is a fully human anti- α v -integrin monoclonal…”
Get full text

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer by EISEN, T, BOSHOFF, C, MAK, I, SAPUNAR, F, VAUGHAN, M. M, PYLE, L, JOHNSTON, S. R. D, AHERN, R, SMITH, I. E, GORE, M. E

“…To grow and metastasize, solid tumours must develop their own blood supply by neo-angiogenesis. Thalidomide inhibits the processing of mRNA encoding peptide…”
Get full text

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens by KRASNER, C. N, MCMEEKIN, D. S, CHAN, S, BRALY, P. S, RENSHAW, F. G, KAYE, S, PROVENCHER, D. M, CAMPOS, S, GORE, M. E

“…The objective of this study was to determine the objective response rate in patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer to…”
Get full text

U.K. guidelines for the management of cutaneous melanoma by Roberts, D.L.L., Anstey, A.V., Barlow, R.J., Cox, N.H., Bishop, J.A. Newton, Corrie, P.G., Evans, J., Gore, M.E., Hall, P.N., Kirkham, N.

“…Summary  These guidelines for management of cutaneous melanoma present evidence‐based guidance for treatment, with identification of the strength of evidence…”
Get full text

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan by GORDON, Alan N, FLEAGLE, John T, GUTHRIE, David, PARKIN, David E, GORE, Martin E, LACAVE, Angel J

“…To compare the efficacy and safety of pegylated liposomal doxorubicin (PLD) and topotecan in patients with epithelial ovarian carcinoma that recurred after or…”
Get full text

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies by Eisen, T, Marais, R, Affolter, A, Lorigan, P, Robert, C, Corrie, P, Ottensmeier, C, Chevreau, C, Chao, D, Nathan, P D, Jouary, T, Harries, M, Negrier, S, Montegriffo, E, Ahmad, T, Gibbens, I, James, M G, Strauss, U P, Prendergast, S, Gore, M E

“…Method: The safety of oral sorafenib up to a maximum protocol-specified dose combined with dacarbazine in patients with metastatic, histologically confirmed…”
Get full text

A phase I II trial of sorafenib and infliximab in advanced renal cell carcinoma by Larkin, J M G, Ferguson, T R, Pickering, L M, Edmonds, K, James, M G, Thomas, K, Banerji, U, Berns, B, de Boer, C, Gore, M E

“…BACKGROUND: There is clinical evidence to suggest that tumour necrosis factor- α (TNF- α ) may be a therapeutic target in renal cell carcinoma (RCC)…”
Get full text

Mucinous ovarian cancer by Harrison, M L, Jameson, C, Gore, M E

“…Mucinous epithelial ovarian cancer (mEOC) accounts for approximately 10% of EOCs. Patients presenting with early-stage disease have an excellent prognosis,…”
Get more information

Temsirolimus in the treatment of advanced renal cell carcinoma by Gore, ME

Get full text

Assessing the impact of evolving evidence in renal cell carcinoma treatment: An update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT) by Gore, M.E, Bellmunt, J, Eisen, T, Escudier, B, Mickisch, G, Patard, J, Porta, C, Ravaud, A, Schmidinger, M, Schöffski, P, Sternberg, C.N, Szczylik, C, Lewis, S, Kirpekar, S

“…Abstract The appropriateness of the numerous therapeutic options available for patients with advanced or metastatic renal cell carcinoma (RCC) was evaluated in…”
Get full text

Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology by Gore, M.E, Bellmunt, J, Eisen, T, Escudier, B, Mickisch, G, Patard, J, Porta, C, Ravaud, A, Schmidinger, M, Schöffski, P, Sternberg, C.N, Szczylik, C, De Nigris, E, Wheeler, C, Kirpekar, S

“…Abstract A diverse range of treatment options and interventions are available for the management of renal cell carcinoma (RCC), allowing clinicians to tailor…”
Get full text

Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer by Bishara, S, Griffin, M, Cargill, A, Bali, A, Gore, M.E, Kaye, S.B, Shepherd, J.H, Van Trappen, P.O

“…Abstract Objective Inflammatory cells can both suppress and stimulate tumour growth and their influence on clinical outcome in cancer patients has been studied…”
Get full text

Second primary melanomas on treatment with vemurafenib: reply from the authors by Fearfield, L., Newton-Bishop, J.A., Sinha, R., Edmonds, K., Gore, M.E., Larkin, J.

Get full text

Significance of tumour calcification in ovarian carcinoma by BURKILL, G. J. C, ALLEN, S. D, A'HERN, R. P, GORE, M. E, KING, D. M

“…The purpose of this study was to assess the pattern and significance of tumour calcification in ovarian carcinoma. Patients with calcifying ovarian carcinoma…”
Get full text